and vasculitis, attributed to overactivity of neutrophil proteases and excessive inflammation. [2] [3] [4] Because of this direct clinical relevance, most studies of AAT have focused on its canonical role as an extracellular protease inhibitor, and augmentation with purified plasma-derived AAT is well established for prevention of emphysema in deficient individuals. [2] [3] [4] Accumulating data, however, suggest that AAT has additional intracellular activities that may contribute to limiting inflammation and restoring homeostasis. These include stabilization of mitochondrial membranes and inhibition of caspases, which together inhibit apoptosis and increase cellular resistance to ischemia ( Figure 1 ). [4] [5] [6] [7] Inhibition of degradation of the inhibitor of NFKB (IKB), and therefore, nuclear factor kappa B (NFKB) activation, and activation of protein phosphatases alter the balance between pro-and anti-inflammatory cytokines and may modulate adaptive as well as innate immunity and promote tolerance. 4, 6, 7 Evidence from cellular and animal models suggests that these novel activities may be beneficial in transplantation.
In this article, we will start by reviewing the novel functions of AAT, then go on to describe the current state of research into the use of AAT in transplantation of islet cells and solid organs. AAT has also been studied for treatment of graft vs host disease following hematopoietic stem cell transplantation, but analysis of that work is beyond the focus and scope of this review.
| NOVEL FUN C TI ON S OF A AT

| Mitochondrial stabilization
Hepatocytes of AAT-deficient patients and mice display mitochondrial injury and increased autophagy, 8 suggesting that AAT may play an important role in stabilizing mitochondrial membranes.
Stabilization of mitochondrial membranes and decreasing release of
Ca++, cytochrome c, and other constituents may explain how AAT protects against induction of diabetes by the mitochondrial poison, streptozotocin (STZ). 9, 10 This effect, and inhibition of pro-apoptotic signaling induced by tumor necrosis factor-α (TNF-α), 10,11 likely contribute to stabilization of pancreatic islet β-cells and to the prevention/treatment of diabetes reported in animal models and in some human studies. 12 Preservation of islets is of obvious interest in pancreas and islet transplantation (discussed in section 3.1, Pancreatic Islet Transplantation). Marcondes et al reported that AAT alters the cellular redox state and improves mitochondrial membrane potential while also increasing expression of antioxidant enzymes such as heme oxygenase 1 ( Figure 1 ). [4] [5] [6] [7] Oxidative stress is important in inflammation and IRI, so these activities may contribute to the ability of AAT to promote cell and tissue survival and modulate inflammatory damage. 10, 11, [13] [14] [15] [16] [17] [18] [19] [20] Because different types of lymphocytes, and cells in different activation states, differ in dependence on glycolysis vs oxidative phosphorylation, modulation of mitochondrial function may influence the balance between sensitization and tolerance. 
| Inhibition of apoptosis
AAT has been shown to inhibit apoptosis in multiple in vitro and in vivo models. 10, 11, [13] [14] [15] [16] [17] [18] [19] [20] Increased cell survival may result not only from stabilization of mitochondrial membranes, but also likely involves direct inhibition of caspases ( Figure 1 ). [4] [5] [6] [7] 10, 11, [13] [14] [15] [16] [17] [18] [19] [20] The molecular mechanism(s) of this inhibition have not been elucidated; caspases are cysteine proteases, while elastase and other canonical targets of
Major intracellular effects of alpha-1-antitrypsin and how they interrelate to achieve physiologic effects. 21 These results emphasize the need for better elucidation of the mechanisms and pathways involved. 
| NFKB activation and cytokine production
| Effects on lymphocytes
It was reported more than 25 years ago that AAT bound to lymphocyte membranes, inhibited their surface proteases, and altered monocyte-lymphocyte interactions. 24 Many effects of AAT may involve inhibition of proteases produced by 1 cell that act on adjacent cells and/or inhibition of protease-activated receptors. Together with intracellular effects, these membrane effects likely contribute to a net decrease in cytokines that favor sensitization, such as IL-1, TNFα, IL-6, and IL-32, while promoting tolerance by preserving transforming growth factor-β and increasing IL-10 and IL-1 receptor antagonist. 4, 6, 7, [24] [25] [26] [27] [28] These effects likely contribute to the induction of regulatory T cells (Tregs) that promote allograft survival. 6, 7, 9, [25] [26] [27] [28] In a mouse model, AAT induced a "cuff" of FoxP3+ Tregs around islet allografts ( Figure 2 ). 7 In both murine and human studies, AAT was reported to modulate donor-derived dendritic cells and to increase CD4+, CD25+ FoxP3+ Tregs. 6 These results suggest that a major net effect of AAT in transplantation may be to shift an inflammatory, sensitizing environment to an anti-inflammatory, tolerance-inducing environment. 28 Initiation of these changes by AAT in the early posttransplant period could decrease the risk of delayed graft function 
| EFFEC TS OF A AT IN CELL AND SOLID ORG AN TR ANS PL ANTATION
Given the multiple effects of AAT that can improve cell survival and function, and potentially reduce immediate and long-term inflammatory and immunologic graft injury, it seems likely that AAT could increase donor organ availability by enabling the use of organs now considered "borderline," decreasing discard rates, and improving transplantation outcomes.
| Pancreatic islet transplantation
Islet transplantation requires extraction of islets from the protease- Many islets gathered for transplantation perish from ischemia and other biologic insults that may begin in the donor, increase during recovery of the pancreas, progress through purification and culture of the islets, then continue posttransplantation until a new blood supply develops. [35] [36] [37] [38] Poor survival of donor islets has imperiled clinical deployment of islet transplantation because multiple donors are required to render a single recipient diabetes-free. An "immediate blood-mediated inflammatory reaction" upon reperfusion of islets is mediated at least in part by increased release of the pro-coagulant "tissue factor" and activation of extracellular protease cascades, which can be inhibited by AAT. 35, 37 The massive, clinically unacceptable loss of islets due first to cell death, then to inflammation and thrombosis in the peritransplant period sensitize the host and are exacerbated by the inability to achieve tolerance.
Thus, initial cellular insults and continuing immunologic damage are inextricably intertwined and diminish the probability of indefinite drug-free islet transplant survival.
AAT has exhibited immediate posttransplant cytoprotective effects upon mouse islet transplants, even with syngeneic donors. 33 More importantly, in an autologous cynomolgus islet model, insidious loss of β-cells was prevented by short-term AAT treatment during the early posttransplant period. 38 While loss of islets and frank diabetes were observed in untreated islet autograft recipients by 180 days posttransplant, AAT-treated recipients had normally functioning grafts for more than 4 years posttransplant. ) for the standard culture media, which contains 10% fetal calf serum.
Reperfusion was then simulated by switching back to serumcontaining medium at 37°C. Compared to controls, addition of human AAT significantly reduced cell mortality in a dose-dependent manner, paralleled by decreased caspase-3 activation, and decreased production of IL-6 and IL-8. 15 In rat models of in situ lung ischemia/ reperfusion and lung transplantation after cold preservation of the donor organ, AAT reduced lung injury and improved function. 15 Encouraged by these results, the same group then conducted a preclinical trial with a pig lung transplant model, in which donor lungs had been preserved at 4°C for 24 hours. Human AAT (240 mg/kg) or albumin (as a control) were given to the porcine recipients 30 minutes before reperfusion. At 4 hours postoperatively, AAT-treated recipients had significant improved lung compliance, decreased wet/ dry ratio, decreased permeability index, and improved exchange of both O 2 and CO 2 . These effects were accompanied by stabilization of IKB and caspase-1 in lung homogenates, decreased apoptosis and caspase 3 in tissue sections, and decreased pro-inflammatory cytokines in plasma (significant for IL-6 and interferon-γ). Plasma neutrophil elastase and circulating thrombin-antithrombin complexes were also decreased. 39 A phase 2 clinical trial of intravenous AAT to prevent primary graft dysfunction in lung transplant is under development at the University of Toronto.
Ex vivo lung perfusion (EVLP) has been introduced to permit objective evaluation of donor lungs before transplantation and reconditioning to improve the function of the organs when necessary.
Optimizing ex vivo perfusion conditions may thus increase donor lung acceptability. Lin et al tested whether addition of AAT (3 mg/mL) to the perfusate improves donor lung function. They stored pig donor lungs at 4°C for 24 hours, then performed EVLP at 37°C for 12 hours.
Compared with donor pig lungs that received perfusate alone, those that received AAT during EVLP had decreased cell death, decreased leakage of Ca++ into the perfusate, improved gas exchange, decreased pulmonary vascular resistance, increased lung compliance, decreased edema, and reduced expression of inflammatory cytokines ex vivo. 40 A preclinical trial of AAT to repair seriously damaged human donor lungs declined from clinical use is currently ongoing. 
| Liver
| Kidney
Although data are limited, it seems likely that AAT could also be beneficial in kidney transplantation. Models of renal IRI reiterate the anti-apoptotic, anti-inflammatory, and immune protective functions of AAT. 13, 41 In rat single kidney allo-transplantation, administration of AAT-primed recipient-strain dendritic cells reduced serum pro-inflammatory cytokines, increased circulating IL-10, increased CD4+, increased Foxp3+ Tregs, and reduced leukocyte infiltration. 42 Effects of AAT on the donor organ per se were not reported.
| Other organs
Only scant information on the effects of AAT in transplantation of other organs (eg, cornea, heart, intestine, and composite tissues)
is available, but some interesting findings have emerged. In animal models of myocardial ischemia/reperfusion and infarction, administration of AAT reduced infarction area, improved left ventricular function, and reduced cellular apoptosis, caspase activation, and leukocyte infiltration. 16 Analogous beneficial effects have been described in a growing number of other models of IRI in situ and in additional transplant models. It seems almost certain that inhibition of multiple types of proteases, not just elastase, are involved. AAT also has lipid-binding and anti-oxidant activities 43 and may directly or indirectly inhibit other signaling cascades not discussed here.
Identification of the mechanisms and development of biomarkers for clinical efficacy could hasten application of AAT and/or development of more efficient synthetic molecules.
| SAFE T Y OF A AT IN H UMAN S
Purified, plasma-derived AAT augmentation therapy for AAT deficiency has been licensed in the United States for nearly 30 years.
Long-term intravenous use of AAT, usually at a dose of 60 mg/kg per week, is well tolerated in AAT-deficient individuals without reports of neutralizing antibodies. 2, 3 In several studies, deficient individuals randomized to treatment with AAT reported fewer adverse events than those receiving placebo (reviewed in references 2 and 3). AAT treatment of cystic fibrosis patients by both inhaled and intravenous routes also appears to be safe and well tolerated despite their chronic infections with Pseudomonas aeruginosa and other bacteria. 44 In early clinical trials for type-1 diabetes, and in small human trials for other conditions, neither acute nor cumulative adverse effects attributable to AAT have emerged.
| FUTURE D IREC TI ON S
Despite advances in organ preservation and immunosuppression, donor graft supply and acceptability continue to limit transplan- which also manufactures and markets human plasma-derived AAT.
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